DMAT(Synonyms: CK2 Inhibitor; Casein kinase II Inhibitor)

DMAT (Synonyms: CK2 Inhibitor; Casein kinase II Inhibitor) 纯度: 98.03%

DMAT 是一种有效的,特异性的 CK2 抑制剂,IC50 值为 130 nM。

DMAT(Synonyms: CK2 Inhibitor;  Casein kinase II Inhibitor)

DMAT Chemical Structure

CAS No. : 749234-11-5

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ¥818 In-stock
10 mg ¥744 In-stock
50 mg ¥2660 In-stock
100 mg   询价  
200 mg   询价  

* Please select Quantity before adding items.

DMAT 相关产品

相关化合物库:

  • Bioactive Compound Library Plus
  • Cell Cycle/DNA Damage Compound Library
  • Kinase Inhibitor Library
  • Stem Cell Signaling Compound Library
  • Wnt/Hedgehog/Notch Compound Library
  • Anti-Cancer Compound Library
  • Anti-Aging Compound Library

生物活性

DMAT is a potent and specific CK2 inhibitor with an IC50 value of 130 nM.

IC50 & Target

CK2

0.13 μM (IC50, Human CK2)

PIM1

0.148 μM (IC50)

PIM2

1.6 μM (IC50)

PIM3

0.097 μM (IC50)

HIPK2

0.37 μM (IC50)

HIPK3

0.59 μM (IC50)

DYRK1a

0.41 μM (IC50)

DYRK2

0.35 μM (IC50)

DYRK3

1.7 μM (IC50)

PKD1

0.18 μM (IC50)

CDK2

0.64 μM (IC50)

体外研究
(In Vitro)

DMAT (1 μM-2.5 μM) DMAT is more efficient in killing antiestrogen resistant cells than parental antiestrogen sensitive MCF-7 cells. DMAT-induced cell death of antiestrogen resistant cells is mediated by caspases. DMAT inhibits CK2 activity but the inhibition is similar in the three cell lines, MCF-7, TAMR-1 and 182R-6[1]. DMAT has effects on H295R cell proliferation at concentrations of 10-4 and 10-5mol/Las compared with the control. DMAT (100 μM) significantly increases apoptosis of H295R cells. DMAT (1 nM-1 μM) significantly decreases aldosterone release into supernatants of 72-h H295R cell cultures as compared with the control[2]. DMAT also inhibits PIM1 by a mechanism which is competitive with respect to ATP, and it is a powerful inhibitor of kinases other than CK2[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

DMAT application in vivo reduces tumor growth in a xenotransplant model by interference with tumor cell proliferation. Biochemical parameters and histology following DMAT administration revealed no alterations in liver tissue[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

476.79

Formula

C9H7Br4N3

CAS 号

749234-11-5

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 50 mg/mL (104.87 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.0974 mL 10.4868 mL 20.9736 mL
5 mM 0.4195 mL 2.0974 mL 4.1947 mL
10 mM 0.2097 mL 1.0487 mL 2.0974 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (5.24 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (5.24 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 MCE 网站选购。
参考文献
  • [1]. Yde CW, et al. Induction of cell death in antiestrogen resistant human breast cancer cells by the protein kinase CK2 inhibitorDMAT. Cancer Lett. 2007 Oct 28;256(2):229-37.

    [2]. Lawnicka H, et al. Anti-neoplastic effect of protein kinase CK2 inhibitor, 2-dimethylamino-4,5,6,7-tetrabromobenzimidazole (DMAT), on growth and hormonal activity of human adrenocortical carcinoma cell line (H295R) in vitro. Cell Tissue Res. 2010 May;340(

    [3]. Pagano MA, et al. The selectivity of inhibitors of protein kinase CK2: an update. Biochem J. 2008 Nov 1;415(3):353-65.

    [4]. Sass G, et al. Inhibition of experimental HCC growth in mice by use of the kinase inhibitor DMAT. Int J Oncol. 2011 Aug;39(2):433-42.

Kinase Assay
[1]

Kinase activity tests are performed in a volume of 50 μL containing (final concentrations): 0.1 μg/μL protein extract, 500 μM CK2 substrate peptide (RRRDDDSDDD), 25 mM Tris-HCl, pH 8.5, 100 μM Na3VO4, 1 mM DTT, 20 mM NaCl, 5 mM MgCl2, 50 μM ATP and appr 1 μCi [γ-32P]-ATP (3000 Ci/mmol). Samples are incubated for 10 min at 30°C. Aliquots are spotted onto P81 phosphocellulose paper and washed 3×5 min in 0.75% phosphoric acid and once in acetone. Incorporation of radiolabelled phosphate is measured by counting the samples in a liquid scintillation counter. Three independent experiments, each done in duplicate, are performed with reproducible results.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay
[2]

H295R cells are plated at a density of 2×104 cells/well into 96-well microplates in complete culture medium and preincubated for 12 h (5% CO2, 37°C, 95% humidity). DMAT in 96% ethanol and Nu-Serum-free culture medium is added to the appropriate wells at final concentrations of 10-4-10-10 M (the highest concentration of ethanol is 1.8% [vol] in the 10-4 M wells). The same volume of Nu-Serum-free culture medium and 96% ethanol is added to the control wells at the same concentration as the solvent in the 10-4 M group. Incubation is performed for 72 h under standard conditions (5% CO2, 37°C, 95% humidity). The absorbance (OD, optical density) of each sample is measured with an enzyme-linked immunosorbent assay (ELISA) microplate reader at a wavelength of 450 nm.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献
  • [1]. Yde CW, et al. Induction of cell death in antiestrogen resistant human breast cancer cells by the protein kinase CK2 inhibitorDMAT. Cancer Lett. 2007 Oct 28;256(2):229-37.

    [2]. Lawnicka H, et al. Anti-neoplastic effect of protein kinase CK2 inhibitor, 2-dimethylamino-4,5,6,7-tetrabromobenzimidazole (DMAT), on growth and hormonal activity of human adrenocortical carcinoma cell line (H295R) in vitro. Cell Tissue Res. 2010 May;340(

    [3]. Pagano MA, et al. The selectivity of inhibitors of protein kinase CK2: an update. Biochem J. 2008 Nov 1;415(3):353-65.

    [4]. Sass G, et al. Inhibition of experimental HCC growth in mice by use of the kinase inhibitor DMAT. Int J Oncol. 2011 Aug;39(2):433-42.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

DMAT(Synonyms: CK2 Inhibitor; Casein kinase II Inhibitor)

DMAT (Synonyms: CK2 Inhibitor; Casein kinase II Inhibitor) 纯度: 98.03%

DMAT 是一种有效的,特异性的 CK2 抑制剂,IC50 值为 130 nM。

DMAT(Synonyms: CK2 Inhibitor;  Casein kinase II Inhibitor)

DMAT Chemical Structure

CAS No. : 749234-11-5

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ¥818 In-stock
10 mg ¥744 In-stock
50 mg ¥2660 In-stock
100 mg   询价  
200 mg   询价  

* Please select Quantity before adding items.

DMAT 相关产品

相关化合物库:

  • Bioactive Compound Library Plus
  • Cell Cycle/DNA Damage Compound Library
  • Kinase Inhibitor Library
  • Stem Cell Signaling Compound Library
  • Wnt/Hedgehog/Notch Compound Library
  • Anti-Cancer Compound Library
  • Anti-Aging Compound Library

生物活性

DMAT is a potent and specific CK2 inhibitor with an IC50 value of 130 nM.

IC50 & Target

CK2

0.13 μM (IC50, Human CK2)

PIM1

0.148 μM (IC50)

PIM2

1.6 μM (IC50)

PIM3

0.097 μM (IC50)

HIPK2

0.37 μM (IC50)

HIPK3

0.59 μM (IC50)

DYRK1a

0.41 μM (IC50)

DYRK2

0.35 μM (IC50)

DYRK3

1.7 μM (IC50)

PKD1

0.18 μM (IC50)

CDK2

0.64 μM (IC50)

体外研究
(In Vitro)

DMAT (1 μM-2.5 μM) DMAT is more efficient in killing antiestrogen resistant cells than parental antiestrogen sensitive MCF-7 cells. DMAT-induced cell death of antiestrogen resistant cells is mediated by caspases. DMAT inhibits CK2 activity but the inhibition is similar in the three cell lines, MCF-7, TAMR-1 and 182R-6[1]. DMAT has effects on H295R cell proliferation at concentrations of 10-4 and 10-5mol/Las compared with the control. DMAT (100 μM) significantly increases apoptosis of H295R cells. DMAT (1 nM-1 μM) significantly decreases aldosterone release into supernatants of 72-h H295R cell cultures as compared with the control[2]. DMAT also inhibits PIM1 by a mechanism which is competitive with respect to ATP, and it is a powerful inhibitor of kinases other than CK2[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

DMAT application in vivo reduces tumor growth in a xenotransplant model by interference with tumor cell proliferation. Biochemical parameters and histology following DMAT administration revealed no alterations in liver tissue[4].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

476.79

Formula

C9H7Br4N3

CAS 号

749234-11-5

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 50 mg/mL (104.87 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.0974 mL 10.4868 mL 20.9736 mL
5 mM 0.4195 mL 2.0974 mL 4.1947 mL
10 mM 0.2097 mL 1.0487 mL 2.0974 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (5.24 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (5.24 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献
  • [1]. Yde CW, et al. Induction of cell death in antiestrogen resistant human breast cancer cells by the protein kinase CK2 inhibitorDMAT. Cancer Lett. 2007 Oct 28;256(2):229-37.

    [2]. Lawnicka H, et al. Anti-neoplastic effect of protein kinase CK2 inhibitor, 2-dimethylamino-4,5,6,7-tetrabromobenzimidazole (DMAT), on growth and hormonal activity of human adrenocortical carcinoma cell line (H295R) in vitro. Cell Tissue Res. 2010 May;340(

    [3]. Pagano MA, et al. The selectivity of inhibitors of protein kinase CK2: an update. Biochem J. 2008 Nov 1;415(3):353-65.

    [4]. Sass G, et al. Inhibition of experimental HCC growth in mice by use of the kinase inhibitor DMAT. Int J Oncol. 2011 Aug;39(2):433-42.

Kinase Assay
[1]

Kinase activity tests are performed in a volume of 50 μL containing (final concentrations): 0.1 μg/μL protein extract, 500 μM CK2 substrate peptide (RRRDDDSDDD), 25 mM Tris-HCl, pH 8.5, 100 μM Na3VO4, 1 mM DTT, 20 mM NaCl, 5 mM MgCl2, 50 μM ATP and appr 1 μCi [γ-32P]-ATP (3000 Ci/mmol). Samples are incubated for 10 min at 30°C. Aliquots are spotted onto P81 phosphocellulose paper and washed 3×5 min in 0.75% phosphoric acid and once in acetone. Incorporation of radiolabelled phosphate is measured by counting the samples in a liquid scintillation counter. Three independent experiments, each done in duplicate, are performed with reproducible results.

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay
[2]

H295R cells are plated at a density of 2×104 cells/well into 96-well microplates in complete culture medium and preincubated for 12 h (5% CO2, 37°C, 95% humidity). DMAT in 96% ethanol and Nu-Serum-free culture medium is added to the appropriate wells at final concentrations of 10-4-10-10 M (the highest concentration of ethanol is 1.8% [vol] in the 10-4 M wells). The same volume of Nu-Serum-free culture medium and 96% ethanol is added to the control wells at the same concentration as the solvent in the 10-4 M group. Incubation is performed for 72 h under standard conditions (5% CO2, 37°C, 95% humidity). The absorbance (OD, optical density) of each sample is measured with an enzyme-linked immunosorbent assay (ELISA) microplate reader at a wavelength of 450 nm.

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献
  • [1]. Yde CW, et al. Induction of cell death in antiestrogen resistant human breast cancer cells by the protein kinase CK2 inhibitorDMAT. Cancer Lett. 2007 Oct 28;256(2):229-37.

    [2]. Lawnicka H, et al. Anti-neoplastic effect of protein kinase CK2 inhibitor, 2-dimethylamino-4,5,6,7-tetrabromobenzimidazole (DMAT), on growth and hormonal activity of human adrenocortical carcinoma cell line (H295R) in vitro. Cell Tissue Res. 2010 May;340(

    [3]. Pagano MA, et al. The selectivity of inhibitors of protein kinase CK2: an update. Biochem J. 2008 Nov 1;415(3):353-65.

    [4]. Sass G, et al. Inhibition of experimental HCC growth in mice by use of the kinase inhibitor DMAT. Int J Oncol. 2011 Aug;39(2):433-42.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

MRT00033659

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

MRT00033659  纯度: 99.18%

MRT00033659 是一种有效的广谱激酶抑制剂,抑制 CK1 (对 CK1δ:IC50=0.9 µM) 和 CHK1 (IC50=0.23 µM)。MRT00033659 是一种吡唑并吡啶类似物,可以诱导 p53 途径活化和 E2F-1 不稳定。

MRT00033659

MRT00033659 Chemical Structure

CAS No. : 1401731-54-1

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
5 mg ¥1500 In-stock
10 mg ¥2500 In-stock
50 mg ¥6500 In-stock
100 mg ¥9500 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

MRT00033659 相关产品

相关化合物库:

  • Bioactive Compound Library Plus

生物活性

MRT00033659 is a potent broad-spectrum kinase inhibitor of CK1 (IC50=0.9 µM for CK1δ) and CHK1 (IC50=0.23 µM). MRT00033659, a pyrazolo-pyridine analogue, induces p53 pathway activation and E2F-1 destabilisation[1].

IC50 & Target[1]

CKIδ

0.9 μM (IC50)

Chk1

0.23 μM (IC50)

体外研究
(In Vitro)

MRT00033659 (5-40 µM; 48 hours) is sufficient to significantly reduce cell number of 5 µM[1].
MRT00033659 (1-80 µM; 48 hours) induces substantial cell death from 5 µM[1].
MRT00033659 (0.2-80 µM; 48 hours) induces a robust and sustained stabilisation of p53, MDM2 and p21 proteins, as well as E2F-1 destabilisation from 0.2 µM to 5 µM[1].
MRT00033659 does not inhibit p38α MAPK[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: A375 cells
Concentration: 5, 20, 40 µM
Incubation Time: 48 hours
Result: Significantly reduced cell number of 5 µM.

Apoptosis Analysis[1]

Cell Line: A375 cells
Concentration: 1, 5, 10, 20, 40, 80 µM
Incubation Time: 48 hours
Result: Induced substantial cell death from 5 µM.

Western Blot Analysis[1]

Cell Line: A375 cells
Concentration: 0.2, 1, 5, 10, 20, 40, 80 µM
Incubation Time: 48 hours
Result: Induced a robust and sustained stabilisation of p53, MDM2 and p21 proteins, as well as E2F-1 destabilisation from 0.2 µM to 5 µM.

分子量

266.30

Formula

C15H14N4O

CAS 号

1401731-54-1

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years

*该产品在溶液状态不稳定,建议您现用现配,即刻使用。

溶解性数据
In Vitro: 

DMSO : 83.33 mg/mL (312.92 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 3.7552 mL 18.7758 mL 37.5516 mL
5 mM 0.7510 mL 3.7552 mL 7.5103 mL
10 mM 0.3755 mL 1.8776 mL 3.7552 mL

*

请根据产品在不同溶剂中的溶解度,选择合适的溶剂配制储备液;该产品在溶液状态不稳定,建议您现用现配,即刻使用

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 4.17 mg/mL (15.66 mM); Clear solution

    此方案可获得 ≥ 4.17 mg/mL (15.66 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 41.7 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 4.17 mg/mL (15.66 mM); Clear solution

    此方案可获得 ≥ 4.17 mg/mL (15.66 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 41.7 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 4.17 mg/mL (15.66 mM); Clear solution

    此方案可获得 ≥ 4.17 mg/mL (15.66 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 41.7 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献
  • [1]. Huart AS, et al. A Casein kinase 1/Checkpoint kinase 1 pyrazolo-pyridine protein kinase inhibitor as novelactivator of the p53 pathway. Bioorg Med Chem Lett. 2013 Oct 15;23(20):5578-85.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

PI-828

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

PI-828 

PI-828 是一种双重 PI3Kcasein kinase 2 (CK2) 抑制剂,抑制 p110αCK2CK2α2IC50 分别为 173 nM,149 nM 和 1127 nM。

PI-828

PI-828 Chemical Structure

CAS No. : 942289-87-4

规格 价格 是否有货
5 mg ¥3500 询问价格 & 货期
10 mg ¥6000 询问价格 & 货期

* Please select Quantity before adding items.

生物活性

PI-828 is a dual PI3K and casein kinase 2 (CK2) inhibitor with IC50s of 173 nM, 149 nM, and 1127 nM for p110α, CK2, and CK2α2 in lipid kinase assay, respectively[1].

IC50 & Target[1]

p110α

173 nM (IC50)

CK2

149 nM (IC50)

CK2α2

1.127 μM (IC50)

体外研究
(In Vitro)

PI-828 (0.01-100 μM) exhibits cytotoxic effect on the 4T1 breast cancer cells and 4306 ovarian cancer cells[2].
PI-828 (0.78-3.12 µM; 48 hours) decreases caspase 3 activation; higher concentrations of PI-828 (6.25-12.5 μM) alone causes apoptosis[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[2]

Cell Line: 4T1 breast cancer cells and 4306 ovarian cancer cells
Concentration: 0.01, 0.1, 1, 10 and 100 μM
Incubation Time:
Result: Exhibited cytotoxic effect.

Apoptosis Analysis[3]

Cell Line: Human embryonic carcinoma NCCIT cells
Concentration: 0.78, 1.56, 3.12, 6.25, 12.5 μM
Incubation Time: 48 hours
Result: Concentrations of ranging from 0.78 to 3.12 µM decreased caspase 3 activation; higher concentrations caused apoptosis.

分子量

322.36

Formula

C19H18N2O3

CAS 号

942289-87-4

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
参考文献
  • [1]. Gharbi SI, et al. Exploring the specificity of the PI3K family inhibitor LY294002. Biochem J. 2007 May 15;404(1):15-21.

    [2]. Kulkarni AA, et al. Supramolecular nanoparticles that target phosphoinositide-3-kinase overcome insulin resistance and exert pronounced antitumor efficacy. Cancer Res. 2013 Dec 1;73(23):6987-97.

    [3]. Zellefrow CD, et al. Identification of druggable targets for radiation mitigation using a small interfering RNA screening assay. Radiat Res. 2012 Sep;178(3):150-9.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Vitamin CK3(Synonyms: 维生素CK3)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

Vitamin CK3 (Synonyms: 维生素CK3) 纯度: 98.95%

Vitamin CK3 是维生素 C 和维生素 K3 的组合 (Vitamin C sodium: Vitamin K3 sodium 为 100:1) ,已被证明可抑制肿瘤生长和在肺部的转移。

Vitamin CK3(Synonyms: 维生素CK3)

Vitamin CK3 Chemical Structure

CAS No. : 1085703-32-7

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ¥550 In-stock
100 mg ¥500 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Vitamin CK3 相关产品

相关化合物库:

  • Bioactive Compound Library Plus
  • Anti-Cancer Compound Library

生物活性

Vitamin CK3 is the combination of Vitamin C and vitamin K3 (100:1 ratio) and has been shown to inhibit tumor growth and lung metastasis.

分子量

474.35

Formula

C17H16Na2O11S

CAS 号

1085703-32-7

中文名称

维生素CK3

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

溶解性数据
In Vitro: 

DMSO : 10 mg/mL (21.08 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.1081 mL 10.5407 mL 21.0815 mL
5 mM 0.4216 mL 2.1081 mL 4.2163 mL
10 mM 0.2108 mL 1.0541 mL 2.1081 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 1 mg/mL (2.11 mM); Clear solution

    此方案可获得 ≥ 1 mg/mL (2.11 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 10.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 1 mg/mL (2.11 mM); Clear solution

    此方案可获得 ≥ 1 mg/mL (2.11 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 10.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 1 mg/mL (2.11 mM); Clear solution

    此方案可获得 ≥ 1 mg/mL (2.11 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 10.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献
  • [1]. Chen MF, et al. Inhibitory effect of vitamin C in combination with vitamin K3 on tumor growth and metastasis of Lewis lung carcinoma xenografted in C57BL/6 mice. Nutr Cancer. 2011;63(7):1036-43.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

CK2 inhibitor 2

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

CK2 inhibitor 2  纯度: 98.12%

CK2 inhibitor 2 是一种有效的,选择性和具有口服活性的 CK2 抑制剂,IC50 值为 0.66 nM。CK2 inhibitor 2 对 Clk2 (IC50=32.69 nM)/CK2 显示出高选择性。 CK2 inhibitor 2 具有良好的抗增殖和抗肿瘤活性。

CK2 inhibitor 2

CK2 inhibitor 2 Chemical Structure

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ¥3300 In-stock
5 mg ¥3000 In-stock
10 mg ¥4800 In-stock
25 mg ¥9500 In-stock
50 mg ¥14500 In-stock
100 mg ¥22500 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

CK2 inhibitor 2 相关产品

相关化合物库:

  • Bioactive Compound Library Plus
  • Cell Cycle/DNA Damage Compound Library
  • Kinase Inhibitor Library
  • Stem Cell Signaling Compound Library
  • Wnt/Hedgehog/Notch Compound Library
  • Anti-Cancer Compound Library
  • Anti-Aging Compound Library
  • Orally Active Compound Library
  • Targeted Diversity Library

生物活性

CK2 inhibitor 2 is a potent, selective and orally active inhibitor of CK2, with an IC50 of 0.66 nM. CK2 inhibitor 2 shows high selectivity for Clk2 (IC50=32.69 nM)/CK2. CK2 inhibitor 2 exhibits favorable antiproliferative and antitumor activity[1].

IC50 & Target[1]

CK2

0.66 nM (IC50)

体外研究
(In Vitro)

CK2 inhibitor 2 (compound 1c) exhibits potent antiproliferative activities against PC-3, HCT-116, MCF-7, HT-29, T24 and LO2 cells, with IC50s of 4.53 μM, 3.07 μM, 7.50 μM, 5.18 μM, 6.10 μM, and 96.68 μM, respectively[1].
CK2 inhibitor 2 (5-20 μM; 24 h) induces apoptosis of HCT-116 cells in a dose-dependent manner. CK2 inhibitor 2 dose-dependently suppresses the expression of p-Akt1S129 and p-Cdc37S13 in HCT-116 cells[1].
CK2 inhibitor 2 (1-500 nM) dose-dependently inhibits exogenous ALDH1A1 enzyme activity, with an IC50 of 0.10 μM[1].
CK2 inhibitor 2 (5-20 μM; 24 h) inhibits the transcription and protein expression of ALDH1A1 in HCT-116 cells[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis[1]

Cell Line: HCT-116 cells
Concentration: 5, 10, 20 μM
Incubation Time: 24 hours
Result: The apoptotic ratio reached about 55% at the concentration of 20 μM.

Western Blot Analysis[1]

Cell Line: HCT-116 cells
Concentration: 5, 10, 20 μM
Incubation Time: 24 hours
Result: Inhibited the expression of p-Akt1S129 and p-Cdc37S13 in a dose-dependent manner.

体内研究
(In Vivo)

CK2 inhibitor 2 (60-90 mg/kg; p.o. twice a day for 4 weeks) obviously inhibits the tumor growth dose-dependently with a maximum inhibitory rate of 69% at a dose of 90 mg/kg[1].
CK2 inhibitor 2 (25 mg/kg; a single p.o.) exhibits Cmax (7017.8 ng/mL), elimination half-life (t1/2=6.67 h), and CL (0.60 L/h/kg) in SD rats[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male BALB/c athymic nude mice (5 weeks old; 16-18 g) were injected HCT-116 cells[1]
Dosage: 60, 90 mg/kg
Administration: P.o. twice a day for 4 weeks
Result: Inhibited the tumor growth in a dose-dependent manner.
No conspicuous change in body weight.
Animal Model: Sprague-Dawley (SD) rats[1]
Dosage: 25 mg/kg (Pharmacokinetic Analysis)
Administration: A single p.o.
Result: Cmax=7017.8 ng/mL, t1/2=6.67 h, CL=0.60 L/h/kg.

分子量

392.84

Formula

C21H17ClN4O2

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 50 mg/mL (127.28 mM; ultrasonic and warming and heat to 60°C)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.5456 mL 12.7278 mL 25.4557 mL
5 mM 0.5091 mL 2.5456 mL 5.0911 mL
10 mM 0.2546 mL 1.2728 mL 2.5456 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: 2.08 mg/mL (5.29 mM); Clear solution; Need ultrasonic

    此方案可获得 2.08 mg/mL (5.29 mM) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献
  • [1]. Wang Y, et, al. Discovery of 5-(3-Chlorophenylamino)benzo[ c][2,6]naphthyridine Derivatives as Highly Selective CK2 Inhibitors with Potent Cancer Cell Stemness Inhibition. J Med Chem. 2021 Apr 22;64(8):5082-5098.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

CK2/ERK8-IN-1

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

CK2/ERK8-IN-1  纯度: ≥99.0%

CK2/ERK8-IN-1 是一种酪蛋白激酶 2 (CK2) (Ki 为 0.25 µM) 和 ERK8 (MAPK15, ERK7) 的双重抑制剂,IC50 均为 0.50 μM。CK2/ERK8-IN-1 还与 PIM1HIPK2DYRK1A 结合,Ki 值分别为 8.65 µM,15.25 µM 和 11.9 µM。CK2/ERK8-IN-1 具有促凋亡 (pro-apoptotic) 作用。

CK2/ERK8-IN-1

CK2/ERK8-IN-1 Chemical Structure

CAS No. : 1085822-09-8

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ¥880 In-stock
10 mg ¥800 In-stock
50 mg ¥3500 In-stock
100 mg ¥6500 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

CK2/ERK8-IN-1 相关产品

相关化合物库:

  • Bioactive Compound Library Plus
  • Apoptosis Compound Library
  • Cell Cycle/DNA Damage Compound Library
  • Epigenetics Compound Library
  • Immunology/Inflammation Compound Library
  • JAK/STAT Compound Library
  • Kinase Inhibitor Library
  • MAPK Compound Library
  • Protein Tyrosine Kinase Compound Library
  • Stem Cell Signaling Compound Library
  • Wnt/Hedgehog/Notch Compound Library
  • Anti-Cancer Compound Library
  • Anti-Aging Compound Library
  • Reprogramming Compound Library
  • Oxygen Sensing Compound Library
  • Glutamine Metabolism Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Angiogenesis Related Compound Library
  • Anti-Liver Cancer Compound Library
  • Anti-Colorectal Cancer Compound Library

生物活性

CK2/ERK8-IN-1 is a dual casein kinase 2 (CK2) (Ki of 0.25 µM) and ERK8 (MAPK15, ERK7) inhibitor with IC50s of 0.50 μM. CK2/ERK8-IN-1 also binds to PIM1, HIPK2 (homeodomain-interacting protein kinase 2), and DYRK1A with Kis of 8.65 µM, 15.25 µM, and 11.9 µM, respectively. CK2/ERK8-IN-1 has pro-apoptotic efficacy[1].

IC50 & Target

CK2

0.5 μM (IC50)

CK2

0.25 μM (Ki)

ERK8

0.5 μM (IC50)

PIM1

8.65 μM (Ki)

HIPK2

15.25 μM (Ki)

DYRK1A

11.9 μM (Ki)

Apoptosis

 

体外研究
(In Vitro)

CK2/ERK8-IN-1 (Compound K66; 0-50 µM; 24 hours; Jurkat cells) treatment displays cytotoxic activity in Jurkat cells[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: Jurkat cells
Concentration: 0-50 µM
Incubation Time: 24 hours
Result: Inhibited cell growth in a dose-dependent manner.

分子量

534.82

Formula

C11H9Br4N3O2

CAS 号

1085822-09-8

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 16.67 mg/mL (31.17 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.8698 mL 9.3489 mL 18.6979 mL
5 mM 0.3740 mL 1.8698 mL 3.7396 mL
10 mM 0.1870 mL 0.9349 mL 1.8698 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: 1.67 mg/mL (3.12 mM); Suspended solution; Need ultrasonic

    此方案可获得 1.67 mg/mL (3.12 mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。

    以 1 mL 工作液为例,取 100 μL 16.7 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: 1.67 mg/mL (3.12 mM); Suspended solution; Need ultrasonic

    此方案可获得 1.67 mg/mL (3.12 mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。

    以 1 mL 工作液为例,取 100 μL 16.7 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 1.67 mg/mL (3.12 mM); Clear solution

    此方案可获得 ≥ 1.67 mg/mL (3.12 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 16.7 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献
  • [1]. Pagano MA, et al. The selectivity of inhibitors of protein kinase CK2: an update. Biochem J. 2008 Nov 1;415(3):353-65.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

CK2/PIM1-IN-1

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

CK2/PIM1-IN-1 

CK2/PIM1-IN-1 是 CK2PIM1 的抑制剂,对 CK2 和 PIM1 作用的 IC50 值分别为 3.787 μM 和 4.327 μM。CK2/PIM1-IN-1 被开发用于增殖性疾病,如癌症,以及其他激酶相关的疾病,包括炎症、疼痛、血管疾病、致病性感染和某些免疫疾病的研究。

CK2/PIM1-IN-1

CK2/PIM1-IN-1 Chemical Structure

CAS No. : 292640-28-9

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

CK2/PIM1-IN-1 is an inhibitor of CK2 and PIM1, with IC50s of 3.787 μM and 4.327 μM for CK2 and PIM1, respectively. CK2/PIM1-IN-1 is developed for the research of proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, vascular disorders, pathogenic infections and certain immunological disorders[1].

IC50 & Target

CK2

3.787 μM (IC50)

PIM1

4.327 μM (IC50)

体外研究
(In Vitro)

CK2/PIM1-IN-1 a PIM kinases and CK2 inhibitor extracted from patent WO2010148351A1, Compound Example 64[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

331.37

Formula

C15H9NO4S2

CAS 号

292640-28-9

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Mustapha Haddach, et al. Rhodanines and related heterocycles as kinase inhibitors. WO2010148351A1.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

CK2/PIM1-IN-1

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

CK2/PIM1-IN-1 

CK2/PIM1-IN-1 是 CK2PIM1 的抑制剂,对 CK2 和 PIM1 作用的 IC50 值分别为 3.787 μM 和 4.327 μM。CK2/PIM1-IN-1 被开发用于增殖性疾病,如癌症,以及其他激酶相关的疾病,包括炎症、疼痛、血管疾病、致病性感染和某些免疫疾病的研究。

CK2/PIM1-IN-1

CK2/PIM1-IN-1 Chemical Structure

CAS No. : 292640-28-9

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

CK2/PIM1-IN-1 is an inhibitor of CK2 and PIM1, with IC50s of 3.787 μM and 4.327 μM for CK2 and PIM1, respectively. CK2/PIM1-IN-1 is developed for the research of proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, vascular disorders, pathogenic infections and certain immunological disorders[1].

IC50 & Target

CK2

3.787 μM (IC50)

PIM1

4.327 μM (IC50)

体外研究
(In Vitro)

CK2/PIM1-IN-1 a PIM kinases and CK2 inhibitor extracted from patent WO2010148351A1, Compound Example 64[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

331.37

Formula

C15H9NO4S2

CAS 号

292640-28-9

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Mustapha Haddach, et al. Rhodanines and related heterocycles as kinase inhibitors. WO2010148351A1.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

CK2/PIM1-IN-1

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

CK2/PIM1-IN-1 

CK2/PIM1-IN-1 是 CK2PIM1 的抑制剂,对 CK2 和 PIM1 作用的 IC50 值分别为 3.787 μM 和 4.327 μM。CK2/PIM1-IN-1 被开发用于增殖性疾病,如癌症,以及其他激酶相关的疾病,包括炎症、疼痛、血管疾病、致病性感染和某些免疫疾病的研究。

CK2/PIM1-IN-1

CK2/PIM1-IN-1 Chemical Structure

CAS No. : 292640-28-9

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

CK2/PIM1-IN-1 is an inhibitor of CK2 and PIM1, with IC50s of 3.787 μM and 4.327 μM for CK2 and PIM1, respectively. CK2/PIM1-IN-1 is developed for the research of proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, vascular disorders, pathogenic infections and certain immunological disorders[1].

IC50 & Target

CK2

3.787 μM (IC50)

PIM1

4.327 μM (IC50)

体外研究
(In Vitro)

CK2/PIM1-IN-1 a PIM kinases and CK2 inhibitor extracted from patent WO2010148351A1, Compound Example 64[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

331.37

Formula

C15H9NO4S2

CAS 号

292640-28-9

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Mustapha Haddach, et al. Rhodanines and related heterocycles as kinase inhibitors. WO2010148351A1.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务